Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (EUR)
Sales 2018 94,0 M
EBIT 2018 -9,76 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
Sales 2019 177 M
EBIT 2019 45,6 M
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 37,2x
Capi. / Sales2019 19,8x
Capitalization 3 498 M
More Financials
Company
Ablynx NV is a is a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand.It includes hematology, inflammation, infectious disease, autoimmune disease, oncology, and immuno-oncology.The company was founded on July... 
More about the company
Latest news on ABLYNX
05/29ABLYNX : Crossing thresholds
CO
05/28ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
05/28ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
05/28ABLYNX : Crossing thresholds
CO
05/25ABLYNX : Notice in relation to the convertible bonds due may 2020
GL
05/25ABLYNX : Crossing thresholds
CO
05/21ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
05/17ABLYNX : 17/05/2018 ablynx announces warrant exercise
PU
05/17ABLYNX : Announces warrant exercise
GL
05/17ABLYNX : Announces warrant exercise
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/02YOUR DAILY PHARMA SCOOP : KPTI Data, Allergan Write-Off, Celgene Down On Delay 
04/30Ablynx completes enrollment in mid-stage study of ALX-0171 in RSV 
03/26Ablynx's vobarilizumab flunks mid-stage lupus study 
03/02Mid-stage study underway in Japan for Ablynx ALX-0171 in RSV 
02/22Ablynx NV reports FY results 
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert K. Zeldin Chief Medical Officer
Robert Freisen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX117.28%0
CELLTRION, INC.--.--%33 987
IQVIA HOLDINGS INC5.50%21 394
LONZA GROUP3.38%20 341
INCYTE CORPORATION-22.25%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836